Objective:

To outline the methodical approach for developing nitrosamine analysis methods and assess current technologies in the context of regulatory compliance.

Key Findings:

• Current technologies can quantify known nitrosamines to proposed limits.
• Unique approaches are required for different formulated products due to varying factors.
• Solid-phase extraction (SPE) enhances detection limits for dilute samples.

Interpretation:

While existing technologies are adequate for many nitrosamines, challenges remain for certain compounds and formulations, necessitating ongoing method development and optimization.

Limitations:

• Not all drug products may be compatible with existing methods.
• Detection limits may still be insufficient for some nitrosamines.

Conclusion:

Continued advancements in detection methods and adherence to regulatory guidelines are essential for effective nitrosamine testing in pharmaceuticals.